Drug Trial Radar · NCT07840365
Optimal Anti-Thrombotic Management Following Percutaneous Left Atrial Appendage Occlusion
Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
234
Planned (sponsor's estimate)
Start
Sep 1, 2026
Primary completion
Dec 15, 2028
Study completion Sep 30, 2029
Sponsor
- Lead sponsor
- Texas Cardiac Arrhythmia Research FoundationAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 25, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized study was designed to compare two antithrombotic regimens (long-term half-dose apixaban vs long-term aspirin after 45-days of full-dose apixaban) after successful Watchman implantation.
Conditions
- Atrial Fibrillation (AF)
Interventions
Half-Dose of novel OACDrug
Patients randomized to long-term half-dose apixaban (Group hdNOAC) will receive half-dose (2.5mg BID) apixaban monotherapy throughout the study period
Low-dose ASADrug
In the low-dose ASA group, patients will receive full-dose of apixaban for 45 days followed by the low-dose aspirin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite endpoint of DRT, TE and major bleeding eventsTime frame: 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Texas Cardiac Arrhythmia Institute, St. David's Medical Center
Austin, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.